COMMUNIQUÉS West-GlobeNewswire

KFSH Demonstrates How Specialized Hospitals Can Drive Health System Innovation at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- Through its sponsorship and participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, King Faisal Specialist Hospital & Research Centre (KFSH) is [...]
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
15/06/2026
Seasoned biopharma executive with extensive experience building and leading organizations and supporting therapeutic pipeline programs in psychiatry MORRISTOWN, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Reunion [...]
Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development
15/06/2026
The companies will combine their complementary expertise in synthetic oligosaccharides, conjugation process development and GMP vaccine manufacturing to support partners developing next-generation conjugate vaccines [...]
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
15/06/2026
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX’s platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including [...]
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
15/06/2026
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T [...]
10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration
15/06/2026
As global soccer fever builds, 10 Barrel Brewing and Pub Beer are bringing fans together across the Pacific Northwest with watch parties, game-day limited-edition merch and activations, sweepstakes and more BEND, Ore., [...]
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
15/06/2026
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, [...]
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
15/06/2026
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- [...]
Immuneering Appoints Andrew Gengos as Chief Financial Officer
15/06/2026
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering [...]
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
15/06/2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster [...]
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel [...]
Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas
15/06/2026
DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli Stilz to the [...]
Sienna Announces June Dividend
15/06/2026
MARKHAM, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
15/06/2026
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- [...]
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
15/06/2026
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S. FESILTY complements Grifols’ bleeding [...]
Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes
15/06/2026
More than 75% of patients screened show elevated cortisol level associated with increased prevalence of cardiovascular disease Inadequate glycemic control despite incretin mimetic use and concomitant hypertension were [...]
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
15/06/2026
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
15/06/2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury [...]
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
15/06/2026
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical [...]

Pages